EA202190056A1 - АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ - Google Patents

АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA202190056A1
EA202190056A1 EA202190056A EA202190056A EA202190056A1 EA 202190056 A1 EA202190056 A1 EA 202190056A1 EA 202190056 A EA202190056 A EA 202190056A EA 202190056 A EA202190056 A EA 202190056A EA 202190056 A1 EA202190056 A1 EA 202190056A1
Authority
EA
Eurasian Patent Office
Prior art keywords
fxii
factor xii
antibodies
xiia
application
Prior art date
Application number
EA202190056A
Other languages
English (en)
Inventor
Дэн Чалоторн
Лори К. Мортон
Линдон Митнол
КехДих Лай
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA202190056A1 publication Critical patent/EA202190056A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F3/00—Amplifiers with only discharge tubes or only semiconductor devices as amplifying elements
    • H03F3/45—Differential amplifiers
    • H03F3/45071—Differential amplifiers with semiconductor devices only
    • H03F3/45076—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier
    • H03F3/45475—Differential amplifiers with semiconductor devices only characterised by the way of implementation of the active amplifying circuit in the differential amplifier using IC blocks as the active amplifying circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • H—ELECTRICITY
    • H03—ELECTRONIC CIRCUITRY
    • H03F—AMPLIFIERS
    • H03F2203/00—Indexing scheme relating to amplifiers with only discharge tubes or only semiconductor devices as amplifying elements covered by H03F3/00
    • H03F2203/45—Indexing scheme relating to differential amplifiers
    • H03F2203/45444—Indexing scheme relating to differential amplifiers the CMCL comprising a sample and hold circuit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Power Engineering (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)

Abstract

Настоящее изобретение относится к моноклональным антителам, которые связываются с белком фактора XII (FXII), и способам их применения. В различных вариантах реализации изобретения антитела представляют собой полностью человеческие антитела, которые связываются с FXII и с активированной формой FXII (FXIIa). В некоторых вариантах реализации изобретенные антитела полезны для ингибирования или нейтрализации активности FXII, обеспечивая, таким образом, средства лечения или предотвращения заболевания, расстройства или состояния, связанного с тромбозом у людей.
EA202190056A 2018-06-19 2019-06-19 АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ EA202190056A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862687144P 2018-06-19 2018-06-19
PCT/US2019/037865 WO2019246176A1 (en) 2018-06-19 2019-06-19 Anti-factor xii/xiia antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202190056A1 true EA202190056A1 (ru) 2021-05-28

Family

ID=67263076

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190056A EA202190056A1 (ru) 2018-06-19 2019-06-19 АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ

Country Status (12)

Country Link
US (1) US20210203292A1 (ru)
EP (1) EP3810270A1 (ru)
JP (1) JP2021527424A (ru)
KR (1) KR20210022650A (ru)
CN (1) CN112437682A (ru)
AU (1) AU2019288299A1 (ru)
CA (1) CA3104470A1 (ru)
EA (1) EA202190056A1 (ru)
IL (1) IL279529A (ru)
MA (1) MA52966A (ru)
MX (1) MX2020013894A (ru)
WO (1) WO2019246176A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021253662A1 (zh) * 2020-06-16 2021-12-23 宁波康善生物科技有限公司 抗fxii纳米抗体或其抗原结合片段及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
US5500349A (en) 1989-01-27 1996-03-19 Coagen Limited Blood-coagulation factor XIIA β monoclonal antibody and immunoassay
WO1991017258A1 (en) * 1990-05-10 1991-11-14 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7378867B1 (en) * 2002-06-04 2008-05-27 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US6891394B1 (en) * 2002-06-04 2005-05-10 Actel Corporation Field-programmable gate array low voltage differential signaling driver utilizing two complimentary output buffers
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
DK1830924T3 (da) 2004-12-23 2013-05-21 Csl Behring Gmbh Forebyggelse af thrombedannelse og/eller -stabilisering
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7582298B2 (en) 2006-06-02 2009-09-01 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human IL-6 receptor
US7541838B2 (en) * 2007-03-27 2009-06-02 Intel Corporation Transmitter swing control circuit and method
RU2522002C2 (ru) 2009-06-26 2014-07-10 Ридженерон Фармасьютикалз, Инк. Легковыделяемые биспецифические антитела с природным иммуноглобулиновым форматом
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
EP2384766A1 (en) * 2010-05-03 2011-11-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel antibody to a carbonic anhydrase
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CA2829037C (en) 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EA037644B1 (ru) 2011-07-19 2021-04-26 Мерк Шарп и Доум Б.В. СПОСОБ ПОЛУЧЕНИЯ Btk-ИНГИБИТОРА
KR102042982B1 (ko) 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 억제성 항-ｘｉｉ/ｘｉｉａ 인자 모노클로날 항체 및 이들의 사용
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
KR101461652B1 (ko) * 2011-12-16 2014-11-21 주식회사 삼양바이오팜 유착방지용 조성물, 이를 포함하는 유착방지기능을 갖는 수술용 메쉬 복합체 및 이의 제조 방법
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
TWI613215B (zh) * 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
WO2014089493A1 (en) * 2012-12-07 2014-06-12 Vanderbilt University Antibodies against factor xii and uses thereof
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9260527B2 (en) * 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
KR20150139089A (ko) * 2014-06-02 2015-12-11 한국전자통신연구원 멀티플라이어 및 다중 입력 증폭기를 포함하는 전류-전압 변환 증폭 회로
JP6709215B2 (ja) * 2014-10-27 2020-06-10 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 抗ｔｉｍ−３抗体
CN111919424A (zh) * 2018-07-02 2020-11-10 拉姆伯斯公司 利用早期高阶符号检测用于判决反馈均衡的方法和电路

Also Published As

Publication number Publication date
WO2019246176A8 (en) 2020-10-08
EP3810270A1 (en) 2021-04-28
US20210203292A1 (en) 2021-07-01
AU2019288299A1 (en) 2021-01-14
IL279529A (en) 2021-01-31
CN112437682A (zh) 2021-03-02
CA3104470A1 (en) 2019-12-26
KR20210022650A (ko) 2021-03-03
MA52966A (fr) 2021-04-28
JP2021527424A (ja) 2021-10-14
WO2019246176A1 (en) 2019-12-26
MX2020013894A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
MX2023001726A (es) Anticuerpos anti-c5 y usos de los mismos.
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
PH12016502064A1 (en) Human antibodies to middle east respiratory syndrome-coronavirus spike protein
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201991643A1 (ru) Человеческие антитела к токсину гемолизину а s.aureus
BR112019010595A2 (pt) anticorpo ou fragmento de ligação ao antígeno do mesmo, combinação de moléculas de ácido nucleico isoladas, composição farmacêutica, kit, e, método para selecionar um composto.
EA202092420A1 (ru) Антитело против pd-l1 и его применение
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
CO2021011944A2 (es) Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021000889A (es) Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
BR112022006620A2 (pt) Anticorpos contra o receptor de poliovírus (pvr) e seus usos
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
EA202190056A1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
EA201891800A1 (ru) Антитела к цитруллинированным hla-полипептидам и их применение